## **SENATE BILL 184**

J5, J4

ENROLLED BILL

(3lr0561)

— Finance / Health and Government Operations —

Introduced by Senators Beidle, Benson, Gile, Hester, and King

Read and Examined by Proofreaders:

													Proofre	ader.
													Proofre	ader.
Sealed	with	the	Great	Seal	and	prese	ented	to	the	Governor,	foi	r his	approval	this
	_ day	of				at						o'clocl	ζ,	M.
						_							Presi	dent.
						CHA	PTER							

## 1 AN ACT concerning

## Health Insurance - Diagnostic and Supplemental Examinations <u>and Biopsies</u> for Breast Cancer - Cost-Sharing

FOR the purpose of prohibiting, except under certain circumstances, insurers, nonprofit
health service plans, and health maintenance organizations that provide coverage
for diagnostic and supplemental breast examinations from imposing a copayment,
coinsurance, or deductible requirement for the examination; requiring the Maryland
<u>Health Care Commission to study and report on the financial impact of eliminating</u>
<u>cost-sharing for diagnostic image-guided biopsies for breast cancer</u>; and generally
relating to health insurance and diagnostic and supplemental examinations and

- 11 <u>*biopsies*</u> for breast cancer.
- 12 BY adding to
- 13 Article Insurance
- 14 Section 15–814.1

## EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.

Italics indicate opposite chamber/conference committee amendments



	2 SENATE BILL 184								
$\frac{1}{2}$	Annotated Code of Maryland (2017 Replacement Volume and 2022 Supplement)								
$\frac{3}{4}$	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:								
5	Article – Insurance								
6	15-814.1.								
7 8	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.								
9 10 11	(2) (I) "DIAGNOSTIC BREAST EXAMINATION" MEANS A MEDICALLY NECESSARY AND APPROPRIATE EXAMINATION OF THE BREAST THAT IS USED TO EVALUATE AN ABNORMALITY THAT IS:								
12 13	1. SEEN OR SUSPECTED FROM A PRIOR SCREENING EXAMINATION FOR BREAST CANCER; OR								
$\begin{array}{c} 14 \\ 15 \end{array}$	2. DETECTED BY ANOTHER MEANS OF PRIOR EXAMINATION.								
16 17 18	(II) "DIAGNOSTIC BREAST EXAMINATION" INCLUDES AN EXAMINATION USING DIAGNOSTIC MAMMOGRAPHY, BREAST MAGNETIC RESONANCE IMAGING, OR BREAST ULTRASOUND.								
19 20 21	(3) (I) "SUPPLEMENTAL BREAST EXAMINATION" MEANS A MEDICALLY NECESSARY EXAMINATION OF THE BREAST THAT IS USED TO SCREEN FOR BREAST CANCER WHEN:								
$\begin{array}{c} 22\\ 23 \end{array}$	1. THERE IS NO ABNORMALITY SEEN OR SUSPECTED FROM A PRIOR EXAMINATION; AND								
$24 \\ 25 \\ 26$	2. THERE IS A PERSONAL OR FAMILY MEDICAL HISTORY OR ADDITIONAL FACTORS THAT MAY INCREASE AN INDIVIDUAL'S RISK OF BREAST CANCER.								
$27 \\ 28 \\ 29$	(II) "SUPPLEMENTAL BREAST EXAMINATION" INCLUDES AN EXAMINATION USING BREAST MAGNETIC RESONANCE IMAGING OR BREAST ULTRASOUND.								
30	(B) THIS SECTION APPLIES TO:								

1 (1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT 2 PROVIDE COVERAGE FOR DIAGNOSTIC BREAST EXAMINATIONS OR SUPPLEMENTAL 3 BREAST EXAMINATIONS UNDER INDIVIDUAL, GROUP, OR BLANKET HEALTH 4 INSURANCE POLICIES OR CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE 5 STATE; AND

6 (2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE 7 COVERAGE FOR DIAGNOSTIC BREAST EXAMINATIONS OR SUPPLEMENTAL BREAST 8 EXAMINATIONS UNDER INDIVIDUAL OR GROUP CONTRACTS THAT ARE ISSUED OR 9 DELIVERED IN THE STATE.

10 (C) (1) SUBJECT TO EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS 11 SUBSECTION, AN ENTITY SUBJECT TO THIS SECTION MAY NOT IMPOSE A 12 COPAYMENT, COINSURANCE, OR DEDUCTIBLE REQUIREMENT ON COVERAGE FOR 13 DIAGNOSTIC BREAST EXAMINATIONS OR SUPPLEMENTAL BREAST EXAMINATIONS.

(2) 14IF THE APPLICATION OF PARAGRAPH (1) OF THIS SUBSECTION TO 15A HEALTH SAVINGS ACCOUNT-QUALIFIED HIGH DEDUCTIBLE HEALTH PLAN WOULD **RESULT IN HEALTH SAVINGS ACCOUNT INELIGIBILITY UNDER § 223 OF THE** 16 **INTERNAL REVENUE CODE. PARAGRAPH (1) OF THIS SUBSECTION SHALL APPLY** 1718 **ONLY WITH RESPECT TO THE DEDUCTIBLE OF THE PLAN AFTER THE ENROLLEE HAS** SATISFIED THE MINIMUM DEDUCTIBLE UNDER § 223 OF THE INTERNAL REVENUE 19 20**CODE** IF AN INSURED OR ENROLLEE IS COVERED UNDER A HIGH-DEDUCTIBLE HEALTH PLAN, AS DEFINED IN 26 U.S.C. § 223, AN ENTITY SUBJECT TO THIS 2122SECTION MAY SUBJECT DIAGNOSTIC BREAST EXAMINATIONS OR SUPPLEMENTAL 23BREAST EXAMINATIONS TO THE DEDUCTIBLE REQUIREMENT OF THE 24HIGH-DEDUCTIBLE HEALTH PLAN.

SECTION 2. AND BE IT FURTHER ENACTED, That on or before October 1, 2023,
 the Maryland Health Care Commission shall study and report to the Governor and, in
 accordance with § 2–1257 of the State Government Article, the Senate Finance Committee
 and the House Health and Government Operations Committee, on the financial impact of
 eliminating health insurance cost–sharing for diagnostic image–guided biopsies for breast
 cancer.

31 <u>SECTION 3. AND BE IT FURTHER ENACTED, That Section 1 of</u> this Act shall 32 apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the 33 State on or after January 1, 2024.

36 <u>SECTION 5. AND BE IT FURTHER ENACTED, That, except as provided in Section</u>
 37 <u>4 of this Act, this Act shall take effect July 1, 2023.</u>

 <sup>34</sup> SECTION <del>3.</del> <u>4.</u> AND BE IT FURTHER ENACTED, That <u>Section 1 of</u> this Act shall
 35 take effect January 1, 2024.